Symbols / IDYA
IDYA Chart
About
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor that is in a Phase 1 clinical trial for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 dose optimization trial; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.82B |
| Enterprise Value | 2.20B | Income | -113.70M | Sales | 218.71M |
| Book/sh | 11.65 | Cash/sh | 7.28 | Dividend Yield | — |
| Payout | 0.00% | Employees | 145 | IPO | — |
| P/E | — | Forward P/E | -9.63 | PEG | — |
| P/S | 12.88 | P/B | 2.75 | P/C | — |
| EV/EBITDA | -14.08 | EV/Sales | 10.08 | Quick Ratio | 10.97 |
| Current Ratio | 11.34 | Debt/Eq | 2.73 | LT Debt/Eq | — |
| EPS (ttm) | -1.28 | EPS next Y | -3.33 | EPS Growth | — |
| Revenue Growth | 55.40% | Earnings | 2026-05-11 | ROA | -8.92% |
| ROE | -10.92% | ROIC | — | Gross Margin | -43.89% |
| Oper. Margin | -8.70% | Profit Margin | -51.99% | Shs Outstand | 87.81M |
| Shs Float | 85.68M | Short Float | 12.54% | Short Ratio | 10.26 |
| Short Interest | — | 52W High | 39.28 | 52W Low | 13.45 |
| Beta | 0.09 | Avg Volume | 915.75K | Volume | 715.82K |
| Target Price | $50.76 | Recom | Strong_buy | Prev Close | $32.11 |
| Price | $32.07 | Change | -0.12% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$50.76
Mean price target
2. Current target
$32.07
Latest analyst target
3. DCF / Fair value
$-10.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$32.07
Low
$31.00
High
$79.00
Mean
$50.76
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-19 | main | Citigroup | Buy → Buy | $65 |
| 2026-02-18 | reit | RBC Capital | Outperform → Outperform | $49 |
| 2026-02-18 | reit | Guggenheim | Buy → Buy | $50 |
| 2026-02-18 | main | Wedbush | Outperform → Outperform | $52 |
| 2026-01-21 | main | RBC Capital | Outperform → Outperform | $45 |
| 2026-01-06 | main | Truist Securities | Buy → Buy | $60 |
| 2025-11-24 | init | Truist Securities | — → Buy | $59 |
| 2025-11-11 | main | Mizuho | Outperform → Outperform | $46 |
| 2025-10-23 | main | JP Morgan | Overweight → Overweight | $79 |
| 2025-10-21 | main | Goldman Sachs | Neutral → Neutral | $30 |
| 2025-10-21 | main | RBC Capital | Outperform → Outperform | $41 |
| 2025-10-21 | reit | BTIG | Buy → Buy | $62 |
| 2025-09-18 | init | Guggenheim | — → Buy | $50 |
| 2025-09-12 | main | Mizuho | Outperform → Outperform | $44 |
| 2025-09-09 | main | RBC Capital | Outperform → Outperform | $38 |
| 2025-09-09 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-09-09 | reit | Stephens & Co. | Overweight → Overweight | $45 |
| 2025-09-08 | main | JMP Securities | Market Outperform → Market Outperform | $45 |
| 2025-09-04 | init | JMP Securities | — → Market Outperform | $41 |
| 2025-09-04 | init | Barclays | — → Overweight | $40 |
- AbbVie cancer R&D leader takes charge of IDEAYA’s drug pipeline - Stock Titan Mon, 23 Feb 2026 11
- IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - PR Newswire ue, 17 Feb 2026 11
- Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? - Yahoo Finance Mon, 02 Feb 2026 08
- A Look At IDEAYA Biosciences (IDYA) Valuation After Reduced Net Losses In Recent Earnings - simplywall.st Wed, 18 Feb 2026 02
- Interesting IDYA Put And Call Options For July 2026 - Nasdaq Fri, 21 Nov 2025 08
- Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away (IDYA) - Seeking Alpha ue, 25 Nov 2025 08
- (IDYA) Movement as an Input in Quant Signal Sets - Stock Traders Daily Sat, 14 Feb 2026 10
- Cantor Fitzgerald Maintains Overweight on IDEAYA (IDYA) Feb 18, 2026 - Meyka Wed, 18 Feb 2026 08
- IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events - PR Newswire Mon, 02 Feb 2026 08
- A Look At IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Pullback - Yahoo Finance Sun, 01 Feb 2026 08
- IDEAYA Biosciences (IDYA) Q4 Loss Of US$83.3 Million Tests Bullish Growth Narrative - simplywall.st hu, 19 Feb 2026 03
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire Fri, 30 Jan 2026 08
- A Closer Look at IDEAYA Biosciences (IDYA) Valuation as Investor Optimism Builds - Yahoo Finance Sat, 29 Nov 2025 08
- Is IDEAYA Biosciences (IDYA) Pricing Reflect Its DCF Upside After Recent Share Pullback - simplywall.st Sat, 31 Jan 2026 08
- IDEAYA Biosciences (NASDAQ: IDYA) to launch Phase 1 IDE034 ADC trial in solid tumors - Stock Titan Mon, 01 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2080 | 54646 | — | Stock Award(Grant) at price 16.91 - 35.62 per share. | SNYDER DOUGLAS B | General Counsel | — | 2025-11-28 00:00:00 | D |
| 1 | 1935 | 60492 | — | Stock Award(Grant) at price 23.26 - 35.62 per share. | RUIZ BRISENO ANDRES | Officer | — | 2025-11-28 00:00:00 | D |
| 2 | 12808 | 250012 | — | Conversion of Exercise of derivative security at price 19.52 per share. | HATA YUJIRO S. | Chief Executive Officer | — | 2025-02-18 00:00:00 | D |
| 3 | 53484 | 415587 | — | Conversion of Exercise of derivative security at price 7.01 - 13.34 per share. | THRONE JASON | Officer | — | 2024-06-27 00:00:00 | D |
| 4 | 28500 | 1032884 | — | Sale at price 36.23 - 36.78 per share. | WHITE MICHAEL ANTHONY | Officer | — | 2024-05-29 00:00:00 | D |
| 5 | 28500 | 366510 | — | Conversion of Exercise of derivative security at price 12.86 per share. | WHITE MICHAEL ANTHONY | Officer | — | 2024-05-29 00:00:00 | D |
| 6 | 175000 | 7397291 | — | Sale at price 41.60 - 44.12 per share. | HATA YUJIRO S. | Chief Executive Officer | — | 2024-05-16 00:00:00 | D |
| 7 | 175000 | 754250 | — | Conversion of Exercise of derivative security at price 4.31 per share. | HATA YUJIRO S. | Chief Executive Officer | — | 2024-05-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -323.14M | -130.42M | -58.99M | -47.24M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -274.48M | -112.96M | -58.66M | -49.76M |
| ReconciledDepreciation | 3.83M | 4.01M | 3.52M | 3.03M |
| EBITDA | -323.14M | -130.42M | -58.99M | -47.24M |
| EBIT | -326.98M | -134.43M | -62.50M | -50.27M |
| NetInterestIncome | 52.50M | 21.47M | 3.85M | 506.00K |
| InterestIncome | 52.50M | 21.47M | 3.85M | 506.00K |
| NormalizedIncome | -274.48M | -112.96M | -58.66M | -49.76M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -274.48M | -112.96M | -58.66M | -49.76M |
| TotalExpenses | 333.98M | 157.81M | 113.43M | 78.21M |
| TotalOperatingIncomeAsReported | -326.98M | -134.43M | -62.50M | -50.27M |
| DilutedAverageShares | 81.68M | 57.52M | 41.44M | 35.25M |
| BasicAverageShares | 81.68M | 57.52M | 41.44M | 35.25M |
| DilutedEPS | -3.36 | -1.96 | -1.42 | -1.41 |
| BasicEPS | -3.36 | -1.96 | -1.42 | -1.41 |
| DilutedNIAvailtoComStockholders | -274.48M | -112.96M | -58.66M | -49.76M |
| NetIncomeCommonStockholders | -274.48M | -112.96M | -58.66M | -49.76M |
| OtherunderPreferredStockDividend | 2.16M | 719.00K | ||
| NetIncome | -274.48M | -112.96M | -58.66M | -49.76M |
| NetIncomeIncludingNoncontrollingInterests | -274.48M | -112.96M | -58.66M | -49.76M |
| NetIncomeContinuousOperations | -274.48M | -112.96M | -58.66M | -49.76M |
| PretaxIncome | -274.48M | -112.96M | -58.66M | -49.76M |
| NetNonOperatingInterestIncomeExpense | 52.50M | 21.47M | 3.85M | 506.00K |
| InterestIncomeNonOperating | 52.50M | 21.47M | 3.85M | 506.00K |
| OperatingIncome | -326.98M | -134.43M | -62.50M | -50.27M |
| OperatingExpense | 333.98M | 157.81M | 113.43M | 78.21M |
| ResearchAndDevelopment | 294.67M | 129.51M | 89.54M | 58.16M |
| SellingGeneralAndAdministration | 39.30M | 28.31M | 23.90M | 20.05M |
| GeneralAndAdministrativeExpense | 39.30M | 28.31M | 23.90M | 20.05M |
| OtherGandA | 39.30M | 28.31M | 23.90M | 20.05M |
| TotalRevenue | 7.00M | 23.39M | 50.93M | 27.94M |
| OperatingRevenue | 7.00M | 23.39M | 50.93M | 27.94M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 86.50M | 65.04M | 48.19M | 38.53M |
| ShareIssued | 86.50M | 65.04M | 48.19M | 38.53M |
| TotalDebt | 19.17M | 2.87M | 3.48M | 5.18M |
| TangibleBookValue | 1.06B | 621.09M | 349.45M | 301.51M |
| InvestedCapital | 1.06B | 621.09M | 349.45M | 301.51M |
| WorkingCapital | 643.64M | 505.53M | 338.74M | 205.84M |
| NetTangibleAssets | 1.06B | 621.09M | 349.45M | 301.51M |
| CapitalLeaseObligations | 19.17M | 2.87M | 3.48M | 5.18M |
| CommonStockEquity | 1.06B | 621.09M | 349.45M | 301.51M |
| TotalCapitalization | 1.06B | 621.09M | 349.45M | 301.51M |
| TotalEquityGrossMinorityInterest | 1.06B | 621.09M | 349.45M | 301.51M |
| StockholdersEquity | 1.06B | 621.09M | 349.45M | 301.51M |
| GainsLossesNotAffectingRetainedEarnings | 812.00K | 562.00K | -2.87M | -712.00K |
| OtherEquityAdjustments | 812.00K | 562.00K | -2.87M | -712.00K |
| RetainedEarnings | -622.84M | -348.36M | -235.40M | -176.75M |
| AdditionalPaidInCapital | 1.68B | 968.88M | 587.72M | 478.97M |
| CapitalStock | 9.00K | 7.00K | 5.00K | 4.00K |
| CommonStock | 9.00K | 7.00K | 5.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 64.94M | 28.23M | 38.51M | 79.83M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 18.87M | 1.12M | 6.80M | 34.67M |
| NonCurrentDeferredLiabilities | 0.00 | 5.18M | 31.19M | |
| NonCurrentDeferredRevenue | 0.00 | 5.18M | 31.19M | |
| LongTermDebtAndCapitalLeaseObligation | 18.87M | 1.12M | 1.61M | 3.48M |
| LongTermCapitalLeaseObligation | 18.87M | 1.12M | 1.61M | 3.48M |
| CurrentLiabilities | 46.07M | 27.10M | 31.72M | 45.16M |
| CurrentDeferredLiabilities | 0.00 | 8.57M | 29.04M | |
| CurrentDeferredRevenue | 0.00 | 8.57M | 29.04M | |
| CurrentDebtAndCapitalLeaseObligation | 298.00K | 1.75M | 1.87M | 1.70M |
| CurrentCapitalLeaseObligation | 298.00K | 1.75M | 1.87M | 1.70M |
| PayablesAndAccruedExpenses | 45.77M | 25.35M | 21.28M | 14.42M |
| CurrentAccruedExpenses | 30.35M | 18.76M | 17.00M | 12.32M |
| Payables | 15.42M | 6.60M | 4.28M | 2.10M |
| AccountsPayable | 15.42M | 6.60M | 4.28M | 2.10M |
| TotalAssets | 1.12B | 649.32M | 387.97M | 381.35M |
| TotalNonCurrentAssets | 434.38M | 116.68M | 17.52M | 130.35M |
| OtherNonCurrentAssets | 805.00K | 782.00K | 205.00K | 397.00K |
| InvestmentsAndAdvances | 405.83M | 107.49M | 8.32M | 121.29M |
| InvestmentinFinancialAssets | 405.83M | 107.49M | 8.32M | 121.29M |
| AvailableForSaleSecurities | 405.83M | 107.49M | 8.32M | 121.29M |
| NetPPE | 27.74M | 8.41M | 8.99M | 8.66M |
| AccumulatedDepreciation | -11.71M | -9.61M | -7.55M | -5.60M |
| GrossPPE | 39.45M | 18.02M | 16.55M | 14.26M |
| Leases | 4.91M | 3.32M | 3.32M | 3.13M |
| OtherProperties | 32.29M | 13.70M | 12.23M | 10.34M |
| MachineryFurnitureEquipment | 2.25M | 999.00K | 998.00K | 787.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 689.71M | 532.63M | 370.45M | 251.00M |
| OtherCurrentAssets | 13.39M | 7.50M | 5.41M | 3.12M |
| PrepaidAssets | 3.12M | |||
| Receivables | 3.00K | 18.00K | 211.00K | 1.10M |
| AccountsReceivable | 3.00K | 18.00K | 211.00K | 1.10M |
| CashCashEquivalentsAndShortTermInvestments | 676.32M | 525.11M | 364.83M | 246.77M |
| OtherShortTermInvestments | 591.94M | 368.10M | 296.20M | 154.72M |
| CashAndCashEquivalents | 84.38M | 157.02M | 68.63M | 92.05M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -251.44M | -117.59M | -90.62M | -58.42M |
| IssuanceOfCapitalStock | 663.63M | 351.94M | 94.96M | 143.25M |
| CapitalExpenditure | -3.86M | -2.37M | -3.44M | -2.64M |
| InterestPaidSupplementalData | 25.00K | 69.00K | 60.00K | 71.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 4.00K | |
| EndCashPosition | 85.18M | 157.78M | 68.74M | 92.15M |
| BeginningCashPosition | 157.78M | 68.74M | 92.15M | 72.14M |
| ChangesInCash | -72.59M | 89.04M | -23.41M | 20.01M |
| FinancingCashFlow | 677.55M | 362.72M | 97.17M | 145.45M |
| CashFlowFromContinuingFinancingActivities | 677.55M | 362.72M | 97.17M | 145.45M |
| ProceedsFromStockOptionExercised | 13.92M | 10.77M | 2.20M | 2.20M |
| NetPreferredStockIssuance | 9.40M | 42.18M | 0.00 | 0.00 |
| PreferredStockIssuance | 9.40M | 42.18M | 0.00 | 0.00 |
| NetCommonStockIssuance | 654.23M | 309.76M | 94.96M | 143.25M |
| CommonStockIssuance | 654.23M | 309.76M | 94.96M | 143.25M |
| InvestingCashFlow | -502.56M | -158.46M | -33.40M | -69.67M |
| CashFlowFromContinuingInvestingActivities | -502.56M | -158.46M | -33.40M | -69.67M |
| NetInvestmentPurchaseAndSale | -498.70M | -156.09M | -29.96M | -67.02M |
| SaleOfInvestment | 692.61M | 439.89M | 225.85M | 247.97M |
| PurchaseOfInvestment | -1.19B | -595.98M | -255.81M | -315.00M |
| NetPPEPurchaseAndSale | -3.86M | -2.37M | -3.44M | -2.64M |
| PurchaseOfPPE | -3.86M | -2.37M | -3.44M | -2.64M |
| OperatingCashFlow | -247.58M | -115.22M | -87.17M | -55.78M |
| CashFlowFromContinuingOperatingActivities | -247.58M | -115.22M | -87.17M | -55.78M |
| ChangeInWorkingCapital | 11.55M | -13.21M | -42.97M | -19.12M |
| ChangeInOtherWorkingCapital | -13.75M | -46.48M | -23.54M | |
| ChangeInOtherCurrentLiabilities | -1.37M | -1.87M | -1.70M | -1.54M |
| ChangeInOtherCurrentAssets | 1.41M | 1.31M | ||
| ChangeInPayablesAndAccruedExpense | 19.07M | 4.27M | 6.44M | 5.38M |
| ChangeInAccruedExpense | 10.79M | 1.64M | 4.57M | 4.21M |
| ChangeInPayable | 8.28M | 2.63M | 1.86M | 1.17M |
| ChangeInAccountPayable | 8.28M | 2.63M | 1.86M | 1.17M |
| ChangeInPrepaidAssets | -6.17M | -2.04M | -2.12M | -189.00K |
| ChangeInReceivables | 15.00K | 193.00K | 892.00K | 774.00K |
| ChangesInAccountReceivables | 15.00K | 193.00K | 892.00K | 774.00K |
| StockBasedCompensation | 34.75M | 18.49M | 11.63M | 8.24M |
| AmortizationOfSecurities | -23.23M | -11.55M | -695.00K | 1.83M |
| DepreciationAmortizationDepletion | 3.83M | 4.01M | 3.52M | 3.03M |
| DepreciationAndAmortization | 3.83M | 4.01M | 3.52M | 3.03M |
| Depreciation | 3.83M | 4.01M | 3.52M | 3.03M |
| GainLossOnSaleOfPPE | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperations | -274.48M | -112.96M | -58.66M | -49.76M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IDYA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|